TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02749994
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02748135
Drug: TB-403 20mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: bi-weekly intravenous doses of TB-403 20mg/kg
Study: NCT02748135
Drug: TB-403 50mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: bi-weekly intravenous doses of TB-403 50mg/kg
Study: NCT02748135
Drug: TB-403 100mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: bi-weekly intravenous doses of TB-403 100mg/kg
Study: NCT02748135
Drug: TB-403 175mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: bi-weekly intravenous doses of TB-403 175mg/kg
Study: NCT01089322
Drug: inhaled corticosteroid plus LABA plus oral corticosteroid
Normalized name: Duramist Plus Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
Study: NCT01167881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 10773
Study: NCT01167881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Glimepiride
Study: NCT01774747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
Study: NCT02552667
Drug: HCP1102+HGP0711Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of HCP1102 with HGP0711 Placebo for 4-week
Study: NCT00337272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken 30 minutes before bedtime days 1-28 of treatment period
Study: NCT02552667
Drug: HCP1102Placebo+HGP0711
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of HCP1102 Placebo with HGP0711 for 4-week
Study: NCT00039351
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00392938
Drug: antiandrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02435368
Drug: mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
Study: NCT01548430
Drug: TTP4000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01548430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005584
Drug: ABVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005584
Drug: BEACOPP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00936832
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00936832
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00936832
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03859414
Drug: Therapeutic Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
Study: NCT03859414
Drug: Therapeutic Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
Study: NCT03859414
Drug: Supra-therapeutic Dose
Normalized name: Supra Sulfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
Study: NCT03859414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 5993 placebo pMDI
Study: NCT04194203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
Study: NCT00518206
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
Study: NCT05570643
Drug: LPS
Normalized name: ALPS LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.
Study: NCT05570643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of NaCl 0.9%.
Study: NCT01902810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth given daily throughout hospitalization
Study: NCT01510795
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
Study: NCT01730027
Drug: ADC3680
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
Study: NCT01730027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
Study: NCT01181726
Drug: Estradiol/Norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/0.5 mg Tablets
Study: NCT01923298
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02807298
Drug: 2% Lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
Study: NCT02807298
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
Study: NCT01620788
Drug: Indapamide / Losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
Study: NCT01620788
Drug: Indapamide / Losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
Study: NCT01620788
Drug: Hyzaar®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Hyzaar®, oral, a day
Study: NCT04304482
Drug: Placebo oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral solution
Study: NCT00470483
Drug: Placebo treatment during 8 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator
Study: NCT02208284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
Study: NCT01868061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Study: NCT00834379
Drug: pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg Tablet
Study: NCT00941499
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2 by vein on Days 1 and 2 of each 21 day cycle.
Study: NCT02556073
Drug: usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
Study: NCT01947114
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01128322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02358096
Drug: ASP8232
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT02358096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT00137007
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03146689
Drug: Topical NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied four times daily
Study: NCT01623401
Drug: TR-701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR-701 FA 200 mg once daily
Study: NCT02621489
Drug: Humulin kwickpen
Normalized name: Humulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humulin kwickpen 10U QD at bedtime
Study: NCT03876886
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih
Study: NCT03727048
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the investigators aimed to evaluate the effect of postoperative ketorolac after ankle fracture surgery on postoperative opioid consumption, pain control, an patient satisfaction.
Study: NCT00650117
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single application
Study: NCT00650117
Drug: Duragesic 25 mcg/h + Scotch Duct Tape (3M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single application
Study: NCT00650117
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single application
Study: NCT00650117
Drug: Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single application
Study: NCT00650117
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single application
Study: NCT00650117
Drug: Duragesic 25 mcg/h + Microfoam Tape (3M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single application
Study: NCT02053142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01201837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly injection
Study: NCT01691677
Drug: placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03436693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once daily
Study: NCT04303520
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/m2/d
Study: NCT00966004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01519557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02666196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02089308
Drug: Test treatment : V0116 transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00657033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
Study: NCT04626739
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/㎡ for D-3 and D-2
Study: NCT04339985
Drug: ATx201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT04339985
Drug: ATx201 OINTMENT vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATx201 OINTMENT vehicle
Study: NCT00003163
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03789578
Drug: NNC0148-0287sema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
Study: NCT01963338
Drug: Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This injection is conducted by needle and syringe in the upper arm (deltoid region).
Study: NCT00378001
Drug: FSH-IBSA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00152464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Oral drops Route of administration: Oral use
Study: NCT03823781
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study intervention is an intravenous infusion of milrinone or placebo.
Study: NCT00260143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01489774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple dose
Study: NCT01489774
Drug: CJ-12406
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single and multiple dose
Study: NCT01271348
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib film tablet, 90 mg, q.d.
Study: NCT01271348
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, q.d.
Study: NCT04001218
Drug: Injection of hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
Study: NCT04001218
Drug: Injection of Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
Study: NCT03785574
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
Study: NCT02158806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule containing inert bulking agent
Study: NCT03280511
Drug: PIPAC
Normalized name: Zagam Respipac
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
Study: NCT03118362
Drug: Plasmalyte
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days.
Study: NCT03118362
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days.
Study: NCT00420199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
Study: NCT00680901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 pills once daily
Study: NCT00680901
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1700mg/m2/day in two daily doses
Study: NCT03821714
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The glucocorticoid group was defined as the use of hydrocortisone alone.
Study: NCT02219659
Drug: Sedation Protocol with Daily Interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
Study: NCT02960035
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01330316
Drug: PegIFN/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN/RBV for 48 weeks
Study: NCT02219659
Drug: Sedation Protocol Without Daily Interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
Study: NCT02219659
Drug: Fentanyl Push First
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
Study: NCT03525548
Drug: VX-445/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received VX-445/TEZ/IVA orally once daily in the morning.
Study: NCT03525548
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received TEZ/IVA orally once daily in the morning.
Study: NCT03525548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
Study: NCT03525548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched TEZ/IVA orally once daily in the morning.
Study: NCT01913535
Drug: CERC-501
Normalized name: CERCIS SILIQUASTRUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days.
Study: NCT01913535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days.
Study: NCT03426202
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 200mg
Study: NCT01864109
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03769402
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid ph1, 50% concentration solution
Study: NCT03769402
Drug: Control Test
Normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, xenograft was used to fill infrabony defects without treating bone surface
Study: NCT02060084
Drug: a probiotic-supplemented group
Approvals — FDA: no, EMA: no, PMDA: no
Description: was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live\>0.5\*107CFU), twice per day, for 2 weeks
Study: NCT00035048
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00055653
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03680586
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo ultra low-dose radiation
Study: NCT02227875
Drug: Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
Study: NCT05462535
Drug: Amosartan Plus Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amosartan Plus Tab., Once daily administered per the locally approved product information
Study: NCT00281905
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes